Real-world adherence to biologic therapies targeting interleukin 17, interleukin 23 and ustekinumab in moderate-to-severe psoriasis: A multicenter cohort study. (PubMed, Farm Hosp) - Oct 15, 2026 - "Adherence to biologic therapies targeting interleukin IL-17, IL-23 and IL-12/23 in patients with moderate-to-severe psoriasis managed in hospital settings for at least 4 months is very high. Systematic assessment of adherence is essential for interpreting clinical outcomes and is essential for persistence analyses."
HEOR • Journal • Real-world evidence • Dermatology • Immunology • Psoriasis • IL12A • IL17A • IL23A
|
|
Amaya Arrondo-Velasco; Joaquín Borrás-Blasco; Maite Sarobe-Carricas; María Calvo-Arbeloa; Ramón San Miguel-Elcano
|